Dr. Yorio on T-DM1 in HER2-Mutant Lung Cancer Treatment

Video

Jeff Yorio, MD, discusses a small phase II study that is looking at using ado-trastuzumab emtansine to treat patients with HER2-mutant metastatic lung cancer.

Jeff Yorio, MD, medical oncologist, Texas Oncology, discusses a small phase II study that is looking at using ado-trastuzumab emtansine (T-DM1; Kadcyla) to treat patients with HER2-mutant metastatic lung cancer.

Patients involved in the study were heavily pretreated with traditional treatments for metastatic lung cancer, including chemotherapy and immunotherapy. The partial response rate to ado-trastuzumab emtansine in this study was 44% and stable disease was observed in 39% of patients.

Ado-trastuzumab emtansine is not yet approved for use in lung cancer; however, the National Comprehensive Cancer Network is recommending the drug for HER2-mutant patients with metastatic lung cancer.

Related Videos
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology
Dimitrios Nasioudis, MD, fellow, Gynecologic Oncology, Perelman School of Medicine, the University of Pennsylvania
Sara Corvigno, MD, PhD, translational researcher, oncology, The University of Texas MD Anderson Cancer Center
I-Chia (Daniel) Liu, MD
Robert W. Mutter, MD
Saad J. Kenderian, MB, CHB, consultant, Division of Hematology, Department of Internal Medicine, Department of Immunology, Department of Molecular Medicine, assistant professor, oncology, immunology, medicine, Mayo Clinic
Mary-Ellen Taplin, MD